Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility - Lupin | Press Release - lupin.com
Lupin's Somerset Manufacturing Facility has received an Establishment Inspection Report (EIR) from the U.S. FDA, indicating compliance with cGMP standards.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 21, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical manufacturers operating under FDA regulations, particularly those involved in cGMP compliance. should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Receipt of EIR signifies that the facility meets FDA's current good manufacturing practices.
Who it affects
All pharmaceutical manufacturers operating under FDA regulations, particularly those involved in cGMP compliance.
What you must do
Review and ensure ongoing compliance with cGMP standards as per FDA guidelines.
Deadline
N/A
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- 10 pharma execs charged with illegally selling 70M Opioid Pill - fda.gov
- Marijuana Rescheduling in Jeopardy? A Federal Court is About to Decide Whether the Attorney General Acted Improperly - newswire.com
- Oklahoma legislature passes law intended to protect 340B drug program - The Journal Record
- Biosimilars substitution bill becomes law in South Dakota - Generics and Biosimilars Initiative
- FDA Allowing Florida to Import Cheaper Drugs from Canada - Supply Chain Brain